A detailed history of Rock Springs Capital Management LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 1,221,309 shares of IMVT stock, worth $33.6 Million. This represents 1.14% of its overall portfolio holdings.

Number of Shares
1,221,309
Previous 1,185,654 3.01%
Holding current value
$33.6 Million
Previous $31.3 Million 7.34%
% of portfolio
1.14%
Previous 0.97%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$27.51 - $27.51 $980,869 - $980,869
35,655 Added 3.01%
1,221,309 $33.6 Million
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $891,828 - $1.12 Million
35,531 Added 3.09%
1,185,654 $31.3 Million
Q1 2024

May 15, 2024

BUY
$30.27 - $43.79 $5.05 Million - $7.31 Million
166,822 Added 16.97%
1,150,123 $37.2 Million
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $10.6 Million - $15 Million
338,957 Added 52.6%
983,301 $41.4 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $12 Million - $25.7 Million
644,344 New
644,344 $24.7 Million
Q1 2021

May 17, 2021

SELL
$13.08 - $49.6 $11.7 Million - $44.2 Million
-891,000 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$36.36 - $52.71 $5.4 Million - $7.83 Million
148,551 Added 20.01%
891,000 $41.2 Million
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $6.56 Million - $11.3 Million
290,130 Added 64.14%
742,449 $26.1 Million
Q2 2020

Aug 14, 2020

BUY
$13.87 - $28.44 $2.81 Million - $5.75 Million
202,319 Added 80.93%
452,319 $11 Million
Q1 2020

May 15, 2020

BUY
$8.36 - $17.13 $2.09 Million - $4.28 Million
250,000 New
250,000 $3.89 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.